GT Biopharma

Company snapshot

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE) platform technology. (NASDAQ: GTBP)

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for GT Biopharma. Not investment advice.

• Peer + 0 momentum

  Kazia Therapeutics

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for GT Biopharma.

1. Jun 8, 2026 Clinical update

   GTM-103 — Approved

2. Jun 5, 2026 Clinical update

   Stereotactic Radiation Therapy — Approved

3. Jun 5, 2026 Clinical update

   Stereotactic Radiation Therapy — Phase 3

4. Jun 5, 2026 Clinical update

   Cesium-131 brachytherapy — Phase 2

5. May 23, 2026 Clinical update

   Temozolomide — Phase 3

View all clinical trial activity →

• What is GT Biopharma?

  GT Biopharma is a biotech organization headquartered in Brisbane, USA. It trades on NYSE under ticker GTBP. Primary therapeutic focus areas include Glioblastoma, Recurrent Brain Metastases, High-risk Myelodysplastic Syndromes, Tri-specific Killer Engager, Obesity (Disorder). Nova

• Is GT Biopharma publicly traded?

  Yes. GT Biopharma is listed with ticker GTBP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does GT Biopharma develop or market?

  We link 7 drug profile(s) where GT Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/gt-biopharma#company-drugs.

• What are the latest developments for GT Biopharma?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does GT Biopharma focus on?

  GT Biopharma focuses on Glioblastoma, Recurrent Brain Metastases, High-risk Myelodysplastic Syndromes based on our analysis of their pipeline programs and drug development activities.